Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Follicular lymphoma, drawn from the whole corpus: 72 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Transformation to DLBCL cannot be predicted or prevented.
Sequencing bispecifics vs CAR-T.
Whether earlier intensive therapy for POD24 patients improves survival.
Late toxicities of decades of therapy (secondary cancers, infections, immunoglobulin loss).
Background: Quality of life. Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 46 changes by month →When this page itself was last checked or edited.
Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.
Accelerated approval in follicular lymphoma
R/R follicular lymphoma after ≥2 lines (accelerated)
R/R follicular lymphoma with lenalidomide and rituximab
Median investigator-assessed progression-free survival 22.